Review: Dopamine agonists are effective for the restless legs syndrome but may be discontinued due to adverse events

Andolsek, Kathryn M.
July 2011
ACP Journal Club;7/19/2011, Vol. 155 Issue 1, p8
Academic Journal
The article reports on a study by H. Scholz and colleagues, focusing on the effectiveness of dopamine agonists in the treatment of restless legs syndrome (RLS). The study concluded that dopamine agonists improved the outcomes more than placebo in the restless legs syndrome. It also showed that however, patients were more likely to discontinue treatment because of adverse events.


Related Articles

  • Effect of Nonergot Dopamine Agonists on Symptoms of Restless Legs Syndrome. Baker, William L.; White, C. Michael; Coleman, Craig I. // Annals of Family Medicine;May/Jun2008, Vol. 6 Issue 3, p253 

    The article presents the findings of the analysis of randomized placebo-controlled trials of nonergot dopamine agonists (NEDAs) for the treatment of restless legs syndrome conducted through July 2007. It is concluded that the use of NEDAs in patients with restless legs syndrome results in the...

  • Review: Nonergot dopamine agonists reduce symptoms in the restless legs syndrome but may be discontinued due to adverse events. Kaushik, Shivu; Blanchard, Amy R. // ACP Journal Club;10/21/2008, Vol. 149 Issue 4, p8 

    The article reports that according to a new study, nonergot dopamine agonists reduce symptoms in the restless legs syndrome but may be discontinued due to their side effects. The study was conducted by researchers W.L. Baker, C.M. White and C.I. Coleman. They found that the drugs pramipexole and...

  • Ropinirole: A Viewpoint by Thomas C. Wetter. Wetter, Thomas C. // CNS Drugs;2004, Vol. 18 Issue 11, p756 

    The article discusses the characteristics of restless legs syndrome (RLS). RLS is a common but often underdiagnosed neurological disorder of unknown aetiology. Ropinirole is a selective dopamine agonist with a non-ergoline structure and is therefore devoid of ergot-related adverse effects. An...

  • Controversies of Dopamine Agonists: Somnolence, Cardiac Valvulopathy and Repetitive Behaviors. Jain, Samay; Waters, Cheryl H. // Current Drug Therapy;Jan2007, Vol. 2 Issue 1, p17 

    The use of dopamine agonists has increased due to their effectiveness in treating symptoms of Parkinson disease (PD) and Restless Leg Syndrome (RLS). Recently, rare but serious adverse effects have been linked to DA agonists, including sudden somnolence, cardiac valvulopathy and repetitive...

  • Pathological gambling plus hypersexuality in restless legs syndrome: a new case. d'Orsi, Giuseppe; Demaio, Vincenzo; Specchio, L. // Neurological Sciences;Aug2011, Vol. 32 Issue 4, p707 

    Emerging clinical data indicate that dopaminergic agonists used to treat restless legs syndrome may be associated with dopamine dysregulation syndrome, particularly pathological gambling. We report a new case with pathological gambling plus hypersexuality and impotence in an old patient treated...

  • Review: Dopamine agonists are effective for the restless legs syndrome but may be discontinued due to adverse events. Andolsek, Kathryn M. // ACP Journal Club;7/19/2011, Vol. 155 Issue 1, p8 

    Question What are the efficacy and safety of dopamine agonists for the restless legs syndrome (RLS)? Review scope Included studies compared dopamine agonists with placebo or other drugs given for >7 days in patients >18 years of age with primary or secondary RLS (International RLS Study Group...

  • Restless Legs Syndrome in the Older Adult: Diagnosis and Management. Milligan, S.A.; Chesson, A.L. // Drugs & Aging;2002, Vol. 19 Issue 10, p741 

    Restless legs syndrome (RLS) is common in the elderly, with an estimated prevalence of 10 to 35% in individuals over 65 years of age. RLS is characterised by paraesthesias and dysaesthesias of the legs, typically occurring in the evening. The symptoms occur at rest and result in motor...

  • IS RLS DRUG BEHIND THIS PATIENT'S SYNCOPE? Porterfield, Linda M. // RN;Dec2007, Vol. 70 Issue 12, p30 

    The article an answer to a question about the possible role of the dopamine agonist ropinirole in a restless legs syndrome patient's syncope.

  • Pramipexole: A Viewpoint by Luigi Ferini-Strambi. Ferini-Strambi, Luigi // CNS Drugs;2007, Vol. 21 Issue 5, p438 

    The article discusses the author view concerning the efficacy of pramipexole in treating restless legs syndrome (RLS). The author stressed out that there were several studies which shows that dopamine agonists control the symptoms of RLS at low dosages and with low risk of augmentation because...


Read the Article


Sign out of this library

Other Topics